Home >> Research Area >> TGF-β/Smad Signaling

TGF-β/Smad Signaling

he transforming growth factor beta (TGFB) signaling pathway is involved in many cellular processes in both the adult organism and the developing embryo including cell growth, cell differentiation, apoptosis, cellular homeostasis and other cellular functions. In spite of the wide range of cellular processes that the TGFβ signaling pathway regulates, the process is relatively simple. TGFβ superfamily ligands bind to a type II receptor, which recruits and phosphorylates a type I receptor. The type I receptor then phosphorylates receptor-regulated SMADs (R-SMADs) which can now bind the coSMAD SMAD4. R-SMAD/coSMAD complexes accumulate in the nucleus where they act as transcription factors and participate in the regulation of target gene expression.

Products for TGF-β/Smad Signaling

  1. Cat.No. Product Name Information
  2. BCC3693 CX-4945 (Silmitasertib) Silmitasertib (CX-4945) is an orally bioavailable, highly selective and potent CK2 inhibitor, with IC50 values of 1 nM against CK2α and CK2α'. CX-4945 (Silmitasertib)
  3. BCC4390 DCC-2036 (Rebastinib) Rebastinib (DCC-2036) is a conformational control Bcr-Abl inhibitor for Abl1WT and Abl1T315I with IC50 of 0.8 nM and 4 nM, also inhibits SRC, KDR, FLT3, and Tie-2, and low activity to seen towards c-Kit. DCC-2036 (Rebastinib)
  4. BCC6646 SC-9 SC-9
  5. BCC6643 SC-10 SC-10
  6. BCN1634 Tamoxifen Tamoxifen (ICI 47699) is a selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells. Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen activates autophagy and induces apoptosis. Tamoxifen
  7. BCC2542 Fasudil (HA-1077) HCl Fasudil Hydrochloride (HA-1077 Hydrochloride; AT877 Hydrochloride), is a nonspecific ROCK inhibitor and also has inhibitory effect on protein kinases, with an Ki of 0.33 μM for ROCK1, IC50s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2 and PKA, PKC, PKG, respectively. Fasudil Hydrochloride is also a potent Ca2+ channel antagonist and vasodilator. Fasudil (HA-1077) HCl
  8. BCC1635 Hydroxyfasudil Hydroxyfasudil is a ROCK inhibitor, with IC50s of 0.73 and 0.72 μM for ROCK1 and ROCK2, respectively. Hydroxyfasudil
  9. BCC3687 LDN-193189 LDN-193189 is a selective BMP signaling inhibitor, inhibits the transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 of 5 nM and 30 nM in C2C12 cells, respectively, exhibits 200-fold selectivity for BMP versus TGF-β. LDN-193189
  10. BCC5331 ML347 ML347(DN193719) is a highly selective ALK1/ALK2 inhibitor with IC50s of 46/32 nM; shows >300-fold selectivity for ALK2 vs. ML347
  11. BCC1695 LDN193189 Hydrochloride LDN-193189 is a selective BMP signaling inhibitor, inhibits the transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 of 5 nM and 30 nM in C2C12 cells, respectively, exhibits 200-fold selectivity for BMP versus TGF-β. LDN193189 Hydrochloride
  12. BCC4302 SR-3677 SR-3677 is a potent and selective ROCK-II inhibitor with an IC50 of ~3 nM. SR-3677
  13. BCC6409 ITD 1 ITD-1 is the first selective TGFβ receptor inhibitor with an IC50 of 460 nM. ITD 1
  14. BCC6414 LX7101 HCL LX7101 is a potent inhibitor of LIMK and ROCK2 with IC50 values of 24, 1.6 and 10 nM for LIMK1, LIMK2 and ROCK2, respectively; also inhibits PKA with an IC50 less than 1 nM. LX7101 HCL
  15. BCC5329 DMH-1 DMH-1 is a potent and selective BMP inhibitor with IC50s of 27/107.9/<5/47.6 nM for ALK1/ALK2/ALK3/ALK6, respectively. DMH-1
  16. BCC5350 Midostaurin (PKC412) Midostaurin (PKC412; CGP 41251) is a multi-targeted protein kinase inhibitor which inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50 ranging from 22-500 nM. Midostaurin (PKC412)
  17. BCC7131 Calphostin C Calphostin C
  18. BCC2525 Thiazovivin Thiazovivin is a potent ROCK inhibitor, which can protect human embryonic stem cells. Thiazovivin improves the efficiency of iPSC generation. Thiazovivin
  19. BCC5830 PKC fragment (530-558) PKC fragment (530-558)
  20. BCC6729 D-erythro-Sphingosine (synthetic) D-erythro-Sphingosine (Erythrosphingosine) is a very potent activator of p32-kinase with an EC50 of 8 μM, and inhibits protein kinase C (PKC). D-erythro-Sphingosine (Erythrosphingosine) is also a PP2A activator. D-erythro-Sphingosine (synthetic)
  21. BCC4295 Ro 31-8220 Ro 31-8220 is a potent PKC inhibitor, with IC50s of 5, 24, 14, 27, 24 and 23 nM for PKCα, PKCβI, PKCβII, PKCγ, PKCε and rat brain PKC, respectively. Ro 31-8220 also significantly inhibits MAPKAP-K1b, MSK1, S6K1 and GSK3β (IC50s, 3, 8, 15, and 38 nM, respectively), with no effect on MKK3, MKK4, MKK6 and MKK7. Ro 31-8220
  22. BCN6327 (-)-Epicatechin gallate (-)-Epicatechin gallate (Epicatechin gallate) inhibits cyclooxygenase-1 (COX-1) with an IC50 of 7.5 μM. (-)-Epicatechin gallate
  23. BCC1480 chroman 1 Chroman 1 is a highly potent ROCK2 inhibitor, with an IC50 of 1 nM. chroman 1
  24. BCC1799 NG25 NG25 is a potent dual TAK1 and MAP4K2 inhibitor, with IC50s of 149 nM and 21.7 nM, respectively. NG25
  25. BCC3704 GF 109203X Bisindolylmaleimide I (GF109203X) is a highly selective, cell-permeable, and reversible protein kinase C (PKC) inhibitor with a Ki of 14 nM. GF 109203X
  26. BCC3705 Go 6983 Go 6983 is a pan-PKC inhibitor against for PKCα, PKCβ, PKCγ, PKCδ and PKCζ with IC50 of 7 nM, 7 nM, 6 nM, 10 nM and 60 nM, respectively. Go 6983
  27. BCC1903 RKI-1447 RKI-1447 is a potent small molecule inhibitor of ROCK1 and ROCK2 with IC50 values of 14.5 nM and 6.2 nM, respectively. RKI-1447
  28. BCC6467 EW-7197 Vactosertib (EW-7197) is a potent, orally active and ATP-competitive activin receptor-like kinase 5 (ALK5) inhibitor with an IC50 of 12.9 nM. Vactosertib also inhibits ALK2 and ALK4 (IC50 of 17.3 nM) at nanomolar concentrations. Vactosertib has potently antimetastatic activity and anticancer effect. EW-7197
  29. BCC3703 Go 6976 Go6976 is a Protein Kinase C (PKC) inhibitor, with an IC50 of 20 nM. Go 6976
  30. BCC7868 Bisindolylmaleimide II Bisindolylmaleimide II
  31. BCC5084 K02288 K02288 is a potent bone morphogenetic protein (BMP) type I receptor inhibitor with IC50s of 1.8, 1.1, 6.4 nM for ALK1, ALK2 and ALK6, respectively. K02288 shows slightly weaker inhibition against ALK3 and ALK6 with IC50s of of 5-34 nM. K02288
  32. BCC5330 LDN-212854 LDN-212854 is a novel BMP inhibitor that exhibits substantially greater selectivity for BMP versus the TGF-β type I receptors; possesses a bias towards ALK2(IC50=1.3 nM) versus ALK1 and ALK3 compared to other inhibitors. LDN-212854
  33. BCC5620 Bryostatin 3 Bryostatin 3
  34. BCC7363 CGP 53353 CGP 53353
  35. BCC4301 Y-27632 Y-27632 is an ATP-competitive inhibitor of ROCK-I and ROCK-II, with Ki of 220 nM and 300 nM for ROCK-I and ROCK-II, respectively, which primes human induced pluripotent stem cells (hIPSCs) to selectively differentiate towards mesendodermal lineage via epithelial-mesenchymal transition-like modulation. Y-27632
  36. BCC1273 Y-27632 dihydrochloride Y-27632 dihydrochloride is an orally active, ATP-competitive inhibitor of ROCK-I and ROCK-II, with Kis of 220 and 300 nM, respectively. Y-27632 dihydrochloride induces apoptosis. Y-27632 dihydrochloride primes human induced pluripotent stem cells (hIPSCs) to selectively differentiate towards mesendodermal lineage via epithelial-mesenchymal transition-like modulation. Y-27632 dihydrochloride
  37. BCC7122 Ro 32-0432 hydrochloride Ro 32-0432 hydrochloride
  38. BCC1636 Hydroxyfasudil hydrochloride Hydroxyfasudil hydrochloride is a ROCK inhibitor, with IC50s of 0.73 and 0.72 μM for ROCK1 and ROCK2, respectively. Hydroxyfasudil hydrochloride
  39. BCC7969 LY 333531 hydrochloride Ruboxistaurin hydrochloride (LY 333531 hydrochloride) is a selective and ATP-competitive PKCβ inhibitor with IC50s of 4.7 nM and 5.9 nM for PKCβI and PKCβII, respectively. Ruboxistaurin hydrochlorid shows less potent inhibition on PKCη (IC50, 52 nM), PKCα (IC50, 360 nM), PKCγ (IC50, 300 nM), PKCδ (IC50, 250 nM), and has no effect on PKCζ (IC50, >100 μM). LY 333531 hydrochloride
  40. BCC1100 Enzastaurin (LY317615) Enzastaurin is a potent and selective PKCβ inhibitor with an IC50 of 6 nM, showing 6- to 20-fold selectivity over PKCα, PKCγ and PKCε. Enzastaurin (LY317615)
  41. BCC5811 PKC β pseudosubstrate PKC β pseudosubstrate
  42. BCC4186 Y-39983 dihydrochloride Y-33075 dihydrochloride is a selective ROCK inhibitor with an IC50 of 3.6 nM. Y-39983 dihydrochloride
  43. BCC1115 Imatinib Mesylate (STI571) Imatinib Mesylate (STI571 Mesylate) is a tyrosine kinases inhibitor that inhibits c-Kit, Bcr-Abl, and PDGFR (IC50=100 nM) tyrosine kinases. Imatinib Mesylate (STI571)
  44. BCC3893 1-Naphthyl PP1 1-Naphthyl PP1(1-NA-PP 1) is a selective inhibitor of src family kinases v-Src and c-Fyn as well as the tyrosine kinase c-Abl (IC50 values are 1.0, 0.6, 0.6, 18 and 22 μM for v-Src, c-Fyn, c-Abl, CDK2 and CAMK II respectively). 1-Naphthyl PP1
  45. BCC5501 K-115 free base Ripasudil free base (K-115 free base) is a specific inhibitor of ROCK, with IC50s of 19 and 51 nM for ROCK2 and ROCK1, respectively. K-115 free base
  46. BCC3890 Adaphostin p210bcr/abl kinase inhibitor Adaphostin
  47. BCC3999 PD173955 PD173955 is src family-selective tyrosine kinase inhibitor with IC50 of ~22 nM for Src, Yes and Abl kinase; less potent for FGFRα and no activity on InsR and PKC. PD173955
  48. BCC7564 FR 236924 DCP-LA (FR236924), a linoleic acid derivative, selectively and directly activates PKCε. FR 236924
  49. BCC3894 PD 180970 p210Bcr/Abl kinase inhibitor; also inhibits c-Src and KIT PD 180970
  50. BCN4732 Narciclasine Narciclasine is a plant growth modulator. Narciclasine modulates the Rho/Rho kinase/LIM kinase/cofilin signaling pathway, greatly increasing GTPase RhoA activity as well as inducing actin stress fiber formation in a RhoA-dependent manner. Narciclasine
  51. BCC3658 SB 431542 SB-431542 is a potent and selective inhibitor of ALK5/TGF-β type I Receptor with an IC50 value of 94 nM. SB 431542
  52. BCC1281 Dasatinib (BMS-354825) Dasatinib (BMS-354825) is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Ki values of 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib (BMS-354825)
  53. BCC6778 Dihydrosphingosine Dihydrosphingosine
  54. BCN5275 Chelerythrine Chelerythrine is a natural alkaloid, acts as a potent and selective Ca2+/phospholopid-dependent PKC antagonist, with an IC50 of 0.7 μM. Chelerythrine has antitumor, antidiabetic and anti-inflammatory activity. Chelerythrine inhibits the BclXL-Bak BH3 peptide binding with IC50 of 1.5 μM and displaces Bax from BclXL. Chelerythrine triggers apoptosis and autophagy. Chelerythrine
  55. BCC1930 SB-505124 hydrochloride SB-505124 hydrochloride is a selective inhibitor of TGF-β Receptor type I receptor (ALK4, ALK5, ALK7), with IC50s of 129 nM and 47 nM for ALK4, ALK5, respectively, but it does not inhibit ALK1, 2, 3, or 6. SB-505124 hydrochloride
  56. BCC2531 SB525334 SB 525334 is a potent and selective transforming growth factor β1 receptor (ALK5) inhibitor with an IC50 of 14.3 nM. SB525334
  57. BCC7870 Phorbol 12,13-dibutyrate Phorbol 12,13-dibutyrate (Phorbol dibutyrate) is a PKC activator and a potent skin tumor promoter. Phorbol 12,13-dibutyrate
  58. BCC1166 Saracatinib (AZD0530) Saracatinib (AZD0530) is a potent Src family inhibitor with IC50s of 2.7 to 11 nM for c-Src, Lck, c-YES, Lyn, Fyn, Fgr, and Blk and shows high selectivity over other tyrosine kinases. Saracatinib (AZD0530)
  59. BCC1167 Bosutinib (SKI-606) Bosutinib is a dual Src/Abl inhibitor with IC50s of 1.2 nM and 1 nM, respectively. Bosutinib (SKI-606)
  60. BCC5085 LY364947 LY-364947 is a potent ATP-competitive inhibitor of TGFβR-I with IC50 of 59 nM, and exhibits 7-fold selectivity over TGFβR-II. LY364947
  61. BCC3857 Sotrastaurin (AEB071) Sotrastaurin is a potent and orally-active pan-PKC inhibitor, with Kis of 0.22 nM, 0.64nM, 0.95 nM, 1.8 nM, 2.1 nM and 3.2 nM for PKCθ, PKCβ, PKCα, PKCη, PKCδ and PKCε, respectively. Sotrastaurin (AEB071)
  62. BCC1887 RepSox RepSox is a potent and selective of the TGFβR-1/ALK5 inhibitor which inhibits ALK5 autophosphorylation with IC50 of 4 nM. RepSox
  63. BCC3666 GW788388 GW788388 is a potent and selective inhibitor of ALK5 with IC50 of 18 nM, and also inhibits TGF-β type II receptor and activin type II receptor activities, without inhibiting BMP type II receptor. GW788388
  64. BCC1538 DPH DPH is a potent cell permeable c-Abl activator, which displays potent enzymatic and cellular activity in stimulating c-Abl activation. DPH
  65. BCN5597 Epicatechin (-)-Epicatechin inhibits cyclooxygenase-1 (COX-1) with an IC50 of 3.2 μM. (-)-Epicatechin inhibits the IL-1β-induced expression of iNOS by blocking the nuclear localization of the p65 subunit of NF-κB. Epicatechin
  66. BCC4998 Dequalinium Chloride Dequalinium Chloride is a selective blocker of apamin-sensitive K+ channels. Dequalinium Chloride
  67. BCC5086 Pirfenidone Pirfenidone (AMR69) is an antifibrotic agent that attenuates CCL2 and CCL12 production in fibrocyte cells. Pirfenidone has growth-inhibitory effect and reduces TGF-β2 protein levels in human glioma cell lines. Pirfenidone also has anti-inflammatory activities. Pirfenidone
  68. BCC1318 A 77-01 A 77-01 is a potent inhibitor of transforming growth factor (TGF)-β type I receptor superfamily activin-like kinase ALK5 with an IC50 of 25 nM. A 77-01
  69. BCC1938 SD-208 SD-208 is a selective TGF-βRI (ALK5) inhibitor with IC50 of 48 nM, and > 100-fold selectivity over TGF-βRII. SD-208
  70. BCC3643 Nilotinib(AMN-107) Nilotinib is an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. Nilotinib(AMN-107)
  71. BCC6718 (±)-Palmitoylcarnitine chloride Palmitoylcarnitine chloride is a fatty acid-derived mitochondrial substrate, and selectively decreases cell survival in colorectal and prostate cancer cells by affecting on pro-inflammatory pathways, Ca2+ influx, and DHT-like effects. (±)-Palmitoylcarnitine chloride
  72. BCC3806 LY2109761 LY2109761 is an orally active, selective TGF-β receptor type I/II inhibitor with Kis of 38 nM and 300 nM, respectively. LY2109761
  73. BCC3709 LY2157299 Galunisertib (LY2157299) is a oral and selective TGF-β receptor type I (TGF-βRI) kinase inhibitor with an IC50 of 56 nM. LY2157299
  74. BCC3891 GNF 2 GNF-2 is a highly selective non-ATP competitive inhibitor of oncogenic Bcr-Abl activity (IC50 = 0.14 μM). GNF 2
  75. BCC3892 GNF 5 GNF-5, an analogue of GNF-2 with improved pharmacokinetic properties, is a selective non-ATP competitive inhibitor of Bcr-Abl with an IC50 value of 0.22±0.1 uM (Wild type Abl). GNF 5
  76. BCC7127 Rottlerin Rottlerin, a natural product purified from Mallotus Philippinensis, is a specific PKC inhibitor, with IC50 values for PKCδ of 3-6 μM, PKCα,β,γ of 30-42 μM, PKCε,η,ζ of 80-100 μM. Rottlerin acts as a direct mitochondrial uncoupler, and stimulates autophagy by targeting a signaling cascade upstream of mTORC1. Rottlerin induces apoptosis via caspase 3 activation. Rottlerin
  77. BCC7343 Bryostatin 1 Bryostatin 1 is a natural macrolide isolated from the bryozoan Bugula neritina and is a potent and central nervous system (CNS)-permeable PKC modulator. Bryostatin 1 binds to the isolated C1 domain of Munc13-1 and the full-length Munc13-1 protein with Kis of 8.07 nM and 0.45 nM, respectively. Bryostatin 1 has anti-cancer, anti-inflammatory, neuroprotective, anti-HIV-1 infection properties. Bryostatin 1
  78. BCC6687 C-1 HA-100 is an inhibitor of cGMP-dependent protein kinase (PKG), cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and MLC-kinase with IC50s of 4, 8, 12 and 240 μM, respectively. C-1
  79. BCC5178 GSK269962A GSK269962A (GSK 269962) is a potent ROCK inhibitor with IC50s of 1.6 and 4 nM for recombinant human ROCK1 and ROCK2 respectively. GSK269962A has anti-inflammatory and vasodilatory activities. GSK269962A
  80. BCC3706 K-252c K-252c, a staurosporine analog isolated from Nocardiopsis sp., is a cell-permeable PKC inhibitor, with an IC50 of 2.45 µM. K-252c induces apoptosis in human chronic myelogenous leukemia cancer cells. K-252c also inhibits β-lactamase, chymotrypsin, and malate dehydrogenase. K-252c
  81. BCN2177 Dasatinib monohydrate Dasatinib monohydrate (BMS-354825 monohydrate) is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Ki values of 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib monohydrate
  82. BCC4003 ZIP Cell-permeable inhibitor of atypical PKC isozyme PKMζ ZIP
  83. BCC2532 GSK429286A GSK429286A is a selective inhibitor of ROCK1 with an IC50 value of 14 nM. GSK429286A
  84. BCC1905 ROCK inhibitor ROCK-IN-2 (Azaindole 1; TC-S 7001) is an orally active and ATP-competitive ROCK inhibitor with IC50s of 0.6 and 1.1 nM for human ROCK-1 and ROCK-2, respectively. ROCK inhibitor
  85. BCC3895 PPY A Potent inhibitor of Abl T315l mutant and wild-type Abl kinases PPY A
  86. BCC5619 Bryostatin 2 Bryostatin 2
  87. BCC4036 Bafetinib (INNO-406) Lyn-IN-1 (Bafetinib analog) is a potent and selective dual Bcr-Abl/Lyn inhibitor, extracted from patent WO2014169128A1. Bafetinib (INNO-406)
  88. BCC1319 A 83-01 A 83-01 is a potent inhibitor of TGF-β type I receptor ALK5 kinase, type I nodal receptor ALK4 and type I nodal receptor ALK7, with IC50s of 12, 45 and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7, respectively. A 83-01
  89. BCC1954 SLx-2119 SLx-2119 (KD-025) is a selective inhibitor of ROCK2 with an IC50 of 105 nM. SLx-2119
  90. BCC1801 Nilotinib monohydrochloride monohydrate Nilotinib monohydrochloride monohydrate is a second generation tyrosine kinase inhibitor (TKI), is significantly potent against BCR-ABL, and is active against many BCR-ABL mutants. Nilotinib monohydrochloride monohydrate
  91. BCC2522 Ponatinib (AP24534) Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively. Ponatinib (AP24534)
  92. BCN4519 (-)-Epigallocatechin(EGC) (-)-Epigallocatechin (EGC) is the most abundant flavonoid in green tea, can bind to unfolded native polypeptides and prevent conversion to amyloid fibrils. (-)-Epigallocatechin(EGC)
  93. BCN6326 (-)-Epigallocatechin gallate (-)-Epigallocatechin Gallate is a tea flavonoid with potent antioxidant, antiinflammatory, and anticarcinogenic properties. (-)-Epigallocatechin Gallate is reported to inhibit EGFR signaling and thereby exert anticancer effects. (-)-Epigallocatechin Gallate (EGCG) is a glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) inhibitor. Epigallocatechin-3-gallate induces oxidative phosphorylation by activating cytochrome c oxidase. (-)-Epigallocatechin gallate
  94. BCC5835 [Ala107]-MBP (104-118) [Ala107]-MBP (104-118)
  95. BCC5836 [Ala113]-MBP (104-118) [Ala113]-MBP (104-118)

Items 1 to 94 of 94 total